# Leash Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leash-bio

- Industry: Biotechnology
- Headquarters: Salt Lake City, US
- Website: www.leash.bio/
- Total disclosed funding: $9.3M
- Latest round: Seed (Apr 5, 2024)
- Investors on record: 5

## About

Founded in 2021 and based in Utah, US, Leash Bio operates as a biotechnology research firm that is building datasets of medicinal chemistry compounds using machine learning. Ian Quigley (CEO) and Andrew Blevins (CTO) are the co-founders of the company. In April 2024, Leash Bio raised USD 9.3 million in seed funding led by SpringTide Capital Management, including Metaplanet Holdings, Top Harvest Capital, Mitsui & Co. Global Investment, and MFV Partners. 

The company offers a proprietary platform that is built upon a dataset compiled through screening of compounds against proteins, resulting in data points. This dataset serves as the foundation for training machine learning models, enabling them to identify drug candidates with accuracy. The firm’s platform also encompasses a cyclical engine that continuously iterates through data collection, machine learning, and refinement processes. Leash Bio’s software further enhances its capabilities, facilitating the design and optimization of chemical matter. 

The organization plans to use the April 2024 funding to support the development of its foundational machine-learning model.

## Funding rounds

- Seed, Apr 5, 2024, $9.3M — Mitsui Global Investment, MFV Partners, Metaplanet Holdings, Top Harvest Capital, SpringTide Capital Management

## Investors

- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Seed
- MFV Partners (https://capitalatlas.ai/funds/mfv-partners) — Seed
- Metaplanet Holdings (https://capitalatlas.ai/funds/metaplanet-holdings) — Seed
- Top Harvest Capital (https://capitalatlas.ai/funds/top-harvest-capital) — Seed
- SpringTide Capital Management (https://capitalatlas.ai/funds/springtide-capital-management) — Seed